High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia

Guangyuan Zeng, Zhiqiang Hu, Michael S. Kinch, Chong-Xian Pan, David A. Flockhart, Chinghai Kao, Thomas A. Gardner, Shaobo Zhang, Lang Li, Lee Ann Baldridge, Michael O. Koch, Thomas M. Ulbright, John N. Eble, Liang Cheng

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas. Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models. Using immunohistochemical analyses, we measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from ninety-three radical prostatectomy specimens. These results were related to multiple clinical and pathological characteristics. The fraction of cells staining positively with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001). Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001). Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examined. Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clinical and pathological parameters examined. Our data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype. Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene. Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.

Original languageEnglish (US)
Pages (from-to)2271-2276
Number of pages6
JournalAmerican Journal of Pathology
Volume163
Issue number6
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

EphA2 Receptor
Prostatic Intraepithelial Neoplasia
Adenocarcinoma
Epithelium
Carcinoma
Receptor Protein-Tyrosine Kinases
Prostatectomy
Oncogenes
Prostate
Prostatic Neoplasms
Animal Models
Epithelial Cells
Monoclonal Antibodies
Staining and Labeling
Phenotype
Growth
Neoplasms

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Zeng, G., Hu, Z., Kinch, M. S., Pan, C-X., Flockhart, D. A., Kao, C., ... Cheng, L. (2003). High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. American Journal of Pathology, 163(6), 2271-2276.

High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. / Zeng, Guangyuan; Hu, Zhiqiang; Kinch, Michael S.; Pan, Chong-Xian; Flockhart, David A.; Kao, Chinghai; Gardner, Thomas A.; Zhang, Shaobo; Li, Lang; Baldridge, Lee Ann; Koch, Michael O.; Ulbright, Thomas M.; Eble, John N.; Cheng, Liang.

In: American Journal of Pathology, Vol. 163, No. 6, 12.2003, p. 2271-2276.

Research output: Contribution to journalArticle

Zeng, G, Hu, Z, Kinch, MS, Pan, C-X, Flockhart, DA, Kao, C, Gardner, TA, Zhang, S, Li, L, Baldridge, LA, Koch, MO, Ulbright, TM, Eble, JN & Cheng, L 2003, 'High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia', American Journal of Pathology, vol. 163, no. 6, pp. 2271-2276.
Zeng, Guangyuan ; Hu, Zhiqiang ; Kinch, Michael S. ; Pan, Chong-Xian ; Flockhart, David A. ; Kao, Chinghai ; Gardner, Thomas A. ; Zhang, Shaobo ; Li, Lang ; Baldridge, Lee Ann ; Koch, Michael O. ; Ulbright, Thomas M. ; Eble, John N. ; Cheng, Liang. / High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia. In: American Journal of Pathology. 2003 ; Vol. 163, No. 6. pp. 2271-2276.
@article{96bfee4573d94895bf8170d9edb124e0,
title = "High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia",
abstract = "EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas. Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models. Using immunohistochemical analyses, we measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from ninety-three radical prostatectomy specimens. These results were related to multiple clinical and pathological characteristics. The fraction of cells staining positively with EphA2 in benign prostatic epithelium (mean, 12{\%}) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67{\%}, P < 0.001) and prostatic adenocarcinoma (mean, 85{\%}, P < 0.001). Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001). Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examined. Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clinical and pathological parameters examined. Our data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype. Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene. Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.",
author = "Guangyuan Zeng and Zhiqiang Hu and Kinch, {Michael S.} and Chong-Xian Pan and Flockhart, {David A.} and Chinghai Kao and Gardner, {Thomas A.} and Shaobo Zhang and Lang Li and Baldridge, {Lee Ann} and Koch, {Michael O.} and Ulbright, {Thomas M.} and Eble, {John N.} and Liang Cheng",
year = "2003",
month = "12",
language = "English (US)",
volume = "163",
pages = "2271--2276",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - High-Level Expression of EphA2 Receptor Tyrosine Kinase in Prostatic Intraepithelial Neoplasia

AU - Zeng, Guangyuan

AU - Hu, Zhiqiang

AU - Kinch, Michael S.

AU - Pan, Chong-Xian

AU - Flockhart, David A.

AU - Kao, Chinghai

AU - Gardner, Thomas A.

AU - Zhang, Shaobo

AU - Li, Lang

AU - Baldridge, Lee Ann

AU - Koch, Michael O.

AU - Ulbright, Thomas M.

AU - Eble, John N.

AU - Cheng, Liang

PY - 2003/12

Y1 - 2003/12

N2 - EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas. Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models. Using immunohistochemical analyses, we measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from ninety-three radical prostatectomy specimens. These results were related to multiple clinical and pathological characteristics. The fraction of cells staining positively with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001). Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001). Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examined. Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clinical and pathological parameters examined. Our data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype. Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene. Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.

AB - EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas. Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models. Using immunohistochemical analyses, we measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from ninety-three radical prostatectomy specimens. These results were related to multiple clinical and pathological characteristics. The fraction of cells staining positively with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001). Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001). Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examined. Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clinical and pathological parameters examined. Our data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype. Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene. Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.

UR - http://www.scopus.com/inward/record.url?scp=10744222309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744222309&partnerID=8YFLogxK

M3 - Article

C2 - 14633601

AN - SCOPUS:10744222309

VL - 163

SP - 2271

EP - 2276

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -